1Q22 Reported With Clinical Updates. Ayala Pharmaceuticals reported a 1Q22 loss of $10.0 million or $(0.66) per share. Interim results from the Phase 2/3 RINGSIDE trial testing AL102 in desmoid tumors are expected to be announced in mid-2022, unchanged from previous guidance. The company also expected to provide updates from the Phase 2 ACCURACY trial testing AL102 in adenoid cystic carcinoma (ACC), and plans to begin a trial in acute lymphoblastic leukemia (ALL) later in 2022. The company ended the quarter with $27.4 million in cash.Looking Forward To Phase 2/3 Ringside Data. The RINGSIDE trial is testing AL102 for treatment of desmoid tumors, a rare tumor of the connective tissue. In February, Ayala announced that Part A of the trial had completed enrollment of 42 patients to evaluate the safety and tolerability, as well as tumor shrinkage at 16 weeks. Upon completion of Part A, the double-blind placebo-controlled Part B will begin testing efficacy with a target enrollment of 156 patients. Read More >>